 |
|||||
| International multicentre phase II and III trials are challenging for the sponsor, due to differences in language, health care systems, regulatory environments, medical practice, and cultural background. From our experience with smaller phase II and larger phase III trials, we have come to learn the importance of respecting the local specificities of each country, while placing extreme importance on assuring high standards and comparable data quality for each participating site. |
For the successful placement of multinational trials, ABX-CRO provides you with all relevant information, not only on epidemiology and suitable investigators, but also on the regulatory environment, health care system, local therapeutic guidelines, or potential competitive projects. With our own or collaborative offices in Australia, Brazil, France, Italy, Japan, South Africa, Switzerland, and the US, and a network of home based pharmaceutical research experts, we provide global clinical coverage, at highest quality, affordable not only for big pharma. |
 Dr. Sabine Friedrich Head Global Operations |
|||
